Partnership to improve heart disease therapy
BIOTRONIK, a global producer of cardio- and endovascular medical products, has announced a strategic partnership with GenesisCare, the largest group of private practice cardiologists in Australia, to enhance outcomes for Australian cardiac patients.
Over the course of three years the partners will initiate interdisciplinary research projects focusing on better data sharing, care pathways and integration, as well as tracking outcomes. BIOTRONIK will contribute its vast technological knowledge to the partnership, while GenesisCare has established systems to monitor and measure patient outcomes.
“With the necessary technology and know-how, we aim to improve patient outcomes with more responsive, personalised and appropriate care,” said Dr Stephen Worthley, Executive Manager at GenesisCare. “This could lead to fewer adverse events, earlier detection of preventable problems and reduced need for hospitalisation.”
Cardiac patients can benefit from this new approach in terms of fewer hospital visits and complications, and lower mortality. This will ultimately translate into lower therapy costs, benefiting patients and health insurers.
“Our partnership aims to overcome obstacles we face when acting alone,” said Jan Ewert, Managing Director of BIOTRONIK Australia and New Zealand. “We look forward to collaborating with GenesisCare to work towards a common goal: redefining how patients receive the best possible care.”
Australians growing more aware of antibiotic resistance
As part of World Antibiotic Awareness Week (12–18 November 2018), NPS MedicineWise has...
Minor protein changes can dramatically impact the immune system
Even minor changes in genetic sequences in HLA molecules can impact dramatically on immune...
Enzyme found to both hinder and help cancer growth
Researchers have solved a longstanding mystery surrounding the protein complex AMPK, long thought...
